Treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. We aimed to investigate the role of partial response and resistance to first gen-SSA in the choice of second line treatments and their outcomes.
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly / Chiloiro, S., Costa, D., Lauretta, R., Mercuri, V., Sbardella, E., Samperi, I., Appetecchia, M., Bianchi, A., Giampietro, A., Gargiulo, P., Isidori, A.M., Poggi, M., Pontecorvi, A., De Marinis, L.. - In: ENDOCRINE. - ISSN 1559-0100. - 78:2(2022), pp. 343-353. [10.1007/s12020-022-03158-w]
Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly
Costa, Denise;Mercuri, Valeria;Sbardella, Emilia;Samperi, Irene;Gargiulo, Patrizia;Isidori, Andrea M;Pontecorvi, Alfredo;
2022
Abstract
Treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. We aimed to investigate the role of partial response and resistance to first gen-SSA in the choice of second line treatments and their outcomes.| File | Dimensione | Formato | |
|---|---|---|---|
|
Chiloiro_Partial-response_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.04 MB
Formato
Adobe PDF
|
1.04 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
